---
figid: PMC3824646__cddis2013309f6
figlink: /pmc/articles/PMC3824646/figure/fig6/
number: F6
caption: Survival pathways in CML progenitors and stem cells. In Bcr-Abl-expressing
  cell lines and CML progenitors, the binding of SCF to its receptor activates the
  PI3K pathway resulting in mTOR and Akt activation. In the absence of Bcr-Abl activity,
  the inhibition of mTOR is sufficient to induce cell death. In stem cells, survival
  is less dependent on the Bcr-Abl activity and was not affected by the mTOR inhibition.
  The activation of the c-kit/PI3K pathway is sufficient to sustain cell survival
pmcid: PMC3824646
papertitle: PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells
  to nilotinib and restore the response of progenitors to nilotinib in the presence
  of stem cell factor.
reftext: K Airiau, et al. Cell Death Dis. 2013 Oct;4(10):e827.
pmc_ranked_result_index: '80538'
pathway_score: 0.8105717
filename: cddis2013309f6.jpg
figtitle: Survival pathways in CML progenitors and stem cells
year: '2013'
organisms:
- Homo sapiens
ndex: 5d58c03e-df26-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3824646__cddis2013309f6.html
  '@type': Dataset
  description: Survival pathways in CML progenitors and stem cells. In Bcr-Abl-expressing
    cell lines and CML progenitors, the binding of SCF to its receptor activates the
    PI3K pathway resulting in mTOR and Akt activation. In the absence of Bcr-Abl activity,
    the inhibition of mTOR is sufficient to induce cell death. In stem cells, survival
    is less dependent on the Bcr-Abl activity and was not affected by the mTOR inhibition.
    The activation of the c-kit/PI3K pathway is sufficient to sustain cell survival
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CG
  - KITLG
  - PIK3R5
  - AKT2
  - AKT3
  - PIK3R3
  - PIK3CD
  - CD34
  - KIT
  - BCR
  - PIK3R6
  - MTOR
  - AKT1
  - PIK3CA
  - PIK3CB
  - PIK3R4
  - LY294002
  - Nilotinib
  - Cancer
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: SCF
  symbol: SCF
  source: hgnc_alias_symbol
  hgnc_symbol: KITLG
  entrez: '4254'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: CD34+/38-
  symbol: CD34
  source: hgnc_symbol
  hgnc_symbol: CD34
  entrez: '947'
- word: C-Kit
  symbol: C-Kit
  source: hgnc_alias_symbol
  hgnc_symbol: KIT
  entrez: '3815'
- word: CML
  symbol: CML
  source: hgnc_alias_symbol
  hgnc_symbol: BCR
  entrez: '613'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
chemicals:
- word: LY294002
  source: MESH
  identifier: C085911
- word: Nilotinib
  source: MESH
  identifier: C498826
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC3824646__F6
redirect_from: /figures/PMC3824646__F6
figtype: Figure
---
